J&J Looks To Get Ahead In Hep B With Combination Strategy
Deal with China's Chia Tai Tianqing Pharmaceutical Group is the latest development in J&J's efforts to develop a curative regimen for hepatitis B. The earlier acquisitions of Alios and Novira and a partnership with Arcturus also factor into the pharma's strategy to attack the virus with a variety of modalities.
You may also be interested in...
J&J’s Comprehensive Approach To Finding A ‘Functional Cure’ For HBV
Capsid assembly modulation, small-interfering RNA, a TLR7 agonist and a DNA-based vaccine are some of the components of the pharma’s strategy for bringing about significant advancement in hepatitis B therapy.
ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy
Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.
Building A US Business: Celltrion’s New CCO Talks Strategy
With Celltrion transitioning to a direct sales model in the US after previously partnering with other firms to market its biosimilars, the company’s new US chief commercial officer, Tom Nusbickel, talks to Generics Bulletin about how the firm is gearing up to launch three key products.